Company intelligence / Profile preview

RPI Intermediate Finance Trust

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

RPI Intermediate Finance Trust is a wholly-owned subsidiary of Royalty Pharma plc, established in 2019 as a Delaware statutory trust. It serves as a holding vehicle for economic interests in biopharmaceutical royalty streams and facilitates financing activities, including debt issuance, to support investments in biopharma royalties and R&D funding. It was integral to Royalty Pharma's 2020 reorganization and IPO.

Industry: Investors

Partnerships

Biohaven Pharmaceutical Holding Company Ltd.Royalty Pharma Investments

Beyond the preview

Go deeper on RPI Intermediate Finance Trust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPI Intermediate Finance Trust.

Explore the full profile